123 related articles for article (PubMed ID: 17122516)
1. The predictive value of CK19 and CD99 in pancreatic endocrine tumors.
Ali A; Serra S; Asa SL; Chetty R
Am J Surg Pathol; 2006 Dec; 30(12):1588-94. PubMed ID: 17122516
[TBL] [Abstract][Full Text] [Related]
2. PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors.
Long KB; Srivastava A; Hirsch MS; Hornick JL
Am J Surg Pathol; 2010 May; 34(5):723-9. PubMed ID: 20414099
[TBL] [Abstract][Full Text] [Related]
3. WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors.
Schmitt AM; Anlauf M; Rousson V; Schmid S; Kofler A; Riniker F; Bauersfeld J; Barghorn A; Probst-Hensch NM; Moch H; Heitz PU; Kloeppel G; Komminoth P; Perren A
Am J Surg Pathol; 2007 Nov; 31(11):1677-82. PubMed ID: 18059224
[TBL] [Abstract][Full Text] [Related]
4. CK19 and CD99 immunoexpression profile in goblet cell (mucin-producing neuroendocrine tumors) and classical carcinoids of the vermiform appendix.
Alsaad KO; Serra S; Perren A; Hsieh E; Chetty R
Int J Surg Pathol; 2007 Jul; 15(3):252-7. PubMed ID: 17652531
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and biological significance of cytokeratin 19 in pancreatic endocrine tumours.
La Rosa S; Rigoli E; Uccella S; Novario R; Capella C
Histopathology; 2007 Apr; 50(5):597-606. PubMed ID: 17394496
[TBL] [Abstract][Full Text] [Related]
6. KIT is an independent prognostic marker for pancreatic endocrine tumors: a finding derived from analysis of islet cell differentiation markers.
Zhang L; Smyrk TC; Oliveira AM; Lohse CM; Zhang S; Johnson MR; Lloyd RV
Am J Surg Pathol; 2009 Oct; 33(10):1562-9. PubMed ID: 19574886
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of CD99 protein expression in pancreatic endocrine tumours (PETs).
Goto A; Niki T; Terado Y; Fukushima J; Fukayama M
Histopathology; 2004 Oct; 45(4):384-92. PubMed ID: 15469477
[TBL] [Abstract][Full Text] [Related]
8. CEACAM1 expression in pancreatic endocrine tumors.
Serra S; Asa SL; Bamberger AM; Wagener C; Chetty R
Appl Immunohistochem Mol Morphol; 2009 Jul; 17(4):286-93. PubMed ID: 19349857
[TBL] [Abstract][Full Text] [Related]
9. Multihormonality and entrapment of islets in pancreatic endocrine tumors.
Kapran Y; Bauersfeld J; Anlauf M; Sipos B; Klöppel G
Virchows Arch; 2006 Apr; 448(4):394-8. PubMed ID: 16418841
[TBL] [Abstract][Full Text] [Related]
10. Proposed histopathologic grading system derived from a study of KIT and CK19 expression in pancreatic endocrine neoplasm.
Zhang L; Lohse CM; Dao LN; Smyrk TC
Hum Pathol; 2011 Mar; 42(3):324-31. PubMed ID: 21190722
[TBL] [Abstract][Full Text] [Related]
11. Paranuclear dot-like immunostaining for CD99: a unique staining pattern for diagnosing solid-pseudopapillary neoplasm of the pancreas.
Guo Y; Yuan F; Deng H; Wang HF; Jin XL; Xiao JC
Am J Surg Pathol; 2011 Jun; 35(6):799-806. PubMed ID: 21566515
[TBL] [Abstract][Full Text] [Related]
12. Loss of membrane localization and aberrant nuclear E-cadherin expression correlates with invasion in pancreatic endocrine tumors.
Chetty R; Serra S; Asa SL
Am J Surg Pathol; 2008 Mar; 32(3):413-9. PubMed ID: 18300809
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical evaluation of solid pseudopapillary tumors of the pancreas: the expression pattern of CD99 is highly unique.
Li L; Li J; Hao C; Zhang C; Mu K; Wang Y; Zhang T
Cancer Lett; 2011 Nov; 310(1):9-14. PubMed ID: 21775056
[TBL] [Abstract][Full Text] [Related]
14. Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors.
Deshpande V; Fernandez-del Castillo C; Muzikansky A; Deshpande A; Zukerberg L; Warshaw AL; Lauwers GY
Am J Surg Pathol; 2004 Sep; 28(9):1145-53. PubMed ID: 15316313
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in pancreatic endocrine tumors.
Srivastava A; Alexander J; Lomakin I; Dayal Y
Hum Pathol; 2001 Nov; 32(11):1184-9. PubMed ID: 11727256
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic study of retinoblastoma including MIB-1, p53, and CD99 immunohistochemistry.
Schwimer CJ; Prayson RA
Ann Diagn Pathol; 2001 Jun; 5(3):148-54. PubMed ID: 11436168
[TBL] [Abstract][Full Text] [Related]
17. Telomerase activity in pancreatic endocrine tumors.
Tang SJ; Dumot JA; Wang L; Memmesheimer C; Conwell DL; Zuccaro G; Goormastic M; Ormsby AH; Cowell J
Am J Gastroenterol; 2002 Apr; 97(4):1022-30. PubMed ID: 12003383
[TBL] [Abstract][Full Text] [Related]
18. Expression of CK19 and KIT in resectable pancreatic neuroendocrine tumors.
Han X; Zhao J; Ji Y; Xu X; Lou W
Tumour Biol; 2013 Oct; 34(5):2881-9. PubMed ID: 23686805
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic endocrine tumors: radiologic-clinicopathologic correlation.
Lewis RB; Lattin GE; Paal E
Radiographics; 2010 Oct; 30(6):1445-64. PubMed ID: 21071369
[TBL] [Abstract][Full Text] [Related]
20. Decreased immunoreactivity of CD99 is an independent predictor of regional lymph node metastases in pulmonary carcinoid tumors.
Pelosi G; Leon ME; Veronesi G; Spaggiari L; Pasini F; Viale G
J Thorac Oncol; 2006 Jun; 1(5):468-77. PubMed ID: 17409901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
